REFERENCES
- Bedlack, R. S., D. Pastula, E. Welsh, D. Pulley, and M. Cudkowicz. 2008. Scrutinizing enrollment in ALS clinical trials: room for improvement. Amyotrophic Lateral Sclerosis 9: 257–265.
- Capdeville, R., T. Krahnke, A. Hatfield, J. M. Ford, I. Van Hoomissen, and I. Gathmann. 2008. Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias. Annals of Oncology 19(7): 1320–1326. doi:10.1093/annonc/mdn050
- Capri, G., J. Chang, S. C. Chen, et al. 2010. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Annals of Oncology 21(3): 474–480. doi:10.1093/annonc/mdp373
- Stahel, R., A. Rossi, L. Petruzelka, et al. 2003. Lessons from the “Iressa” Expanded Access Programme: Gefitinib in special non-small-cell lung cancer patient populations. British Journal of Cancer 89(Suppl. 2): S19–S23.
- Walker, M. J., W. A. Rogers, and V. Entwistle. 2014. Ethical justifications for access to unapproved medical interventions: An argument for (limited) patient obligations. American Journal of Bioethics 14(11): XX–XX.
- Wasner, M., H. Klier, and G. Borasio. 2001. The use of alternative medicine by patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences 191: 151–154.